Castle Hook Partners LP Raises Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Castle Hook Partners LP raised its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 25.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 135,273 shares of the medical equipment provider's stock after acquiring an additional 27,132 shares during the quarter. Intuitive Surgical makes up about 0.9% of Castle Hook Partners LP's portfolio, making the stock its 22nd largest holding. Castle Hook Partners LP's holdings in Intuitive Surgical were worth $70,607,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its position in Intuitive Surgical by 1.5% during the 3rd quarter. Principal Financial Group Inc. now owns 602,393 shares of the medical equipment provider's stock valued at $295,938,000 after purchasing an additional 9,194 shares during the period. World Investment Advisors LLC acquired a new stake in shares of Intuitive Surgical during the third quarter worth $228,000. Nordea Investment Management AB raised its stake in Intuitive Surgical by 31.7% during the fourth quarter. Nordea Investment Management AB now owns 43,200 shares of the medical equipment provider's stock worth $22,632,000 after buying an additional 10,405 shares during the last quarter. Capital Market Strategies LLC lifted its holdings in Intuitive Surgical by 7.8% in the fourth quarter. Capital Market Strategies LLC now owns 1,237 shares of the medical equipment provider's stock valued at $646,000 after buying an additional 90 shares during the period. Finally, Diversified Trust Co boosted its position in Intuitive Surgical by 0.6% during the fourth quarter. Diversified Trust Co now owns 4,383 shares of the medical equipment provider's stock valued at $2,288,000 after acquiring an additional 25 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Jami K. Nachtsheim sold 2,400 shares of Intuitive Surgical stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the transaction, the director now owns 6,371 shares in the company, valued at $3,312,920. This trade represents a 27.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Robert Desantis sold 188 shares of the company's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $515.91, for a total transaction of $96,991.08. Following the sale, the executive vice president now owns 5,224 shares in the company, valued at $2,695,113.84. The trade was a 3.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,313 shares of company stock valued at $17,229,143 over the last ninety days. 0.70% of the stock is currently owned by insiders.

Intuitive Surgical Trading Down 0.3 %

Shares of NASDAQ:ISRG traded down $1.61 during midday trading on Friday, reaching $536.55. The company had a trading volume of 925,598 shares, compared to its average volume of 1,628,568. Intuitive Surgical, Inc. has a 52-week low of $379.67 and a 52-week high of $616.00. The company's 50 day moving average price is $500.93 and its 200 day moving average price is $534.71. The stock has a market cap of $192.31 billion, a P/E ratio of 83.71, a P/E/G ratio of 5.85 and a beta of 1.70.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. The firm had revenue of $2.25 billion during the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a net margin of 27.81% and a return on equity of 14.55%. During the same period in the prior year, the firm earned $1.50 EPS. Research analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Royal Bank of Canada dropped their price objective on Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. CICC Research assumed coverage on Intuitive Surgical in a research note on Monday, January 27th. They issued a "neutral" rating and a $550.00 price target on the stock. Wells Fargo & Company raised their price objective on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. JPMorgan Chase & Co. boosted their target price on shares of Intuitive Surgical from $575.00 to $675.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Finally, Truist Financial reduced their price target on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and an average target price of $598.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.